Sugi Predict

Sugi Predict / Targets / JMJD7

JMJD7

Bifunctional peptidase and (3S)-lysyl hydroxylase JMJD7 · P0C870 · JMJD7 on Sugi Atlas →

1,828 patent compounds predicted against JMJD7, 1,409 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Vidofludimus Vidofludimus (SCHEMBL247888) 1.00 1/20
SCHEMBL5090192 SCHEMBL5090192 1.00 1/20
SCHEMBL4397456 SCHEMBL4397456 0.84 1/20
SCHEMBL13836221 SCHEMBL13836221 0.82 1/20
SCHEMBL13836461 SCHEMBL13836461 0.82 1/20
SCHEMBL14907817 SCHEMBL14907817 0.82 1/20
SCHEMBL15783085 SCHEMBL15783085 0.82 1/20
SCHEMBL3925167 SCHEMBL3925167 0.82 1/20
SCHEMBL4389409 SCHEMBL4389409 0.81 1/20
SCHEMBL254247 SCHEMBL254247 0.79 1/20
SCHEMBL503290 SCHEMBL503290 0.78 1/20
SCHEMBL14452166 SCHEMBL14452166 0.78 1/20
SCHEMBL3917145 SCHEMBL3917145 0.77 1/20
SCHEMBL15488980 SCHEMBL15488980 0.77 1/20
SCHEMBL15783114 SCHEMBL15783114 0.77 1/20
SCHEMBL15783133 SCHEMBL15783133 0.77 1/20
SCHEMBL15783134 SCHEMBL15783134 0.77 1/20
SCHEMBL11955293 SCHEMBL11955293 0.77 1/20
SCHEMBL9965609 SCHEMBL9965609 0.77 1/20
SCHEMBL2153142 SCHEMBL2153142 0.76 1/20

Clinical trials — most relevant to JMJD7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer PHASE1/PHASE2RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy PHASE2NOT_YET_RECRUITING
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. PHASE2UNKNOWN
Vorinostat in Children PHASE1/PHASE2COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma PHASE1RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19 nanCOMPLETED
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer nanUNKNOWN
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis nanCOMPLETED
Mechanisms of Immune Deficiency nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a JMJD7 binder may also engage these)

ProteinNameSimilarity
P0C872 — 1.000 P0C872 →
Q0WVR4 — 0.970 Q0WVR4 →
Q08BV2 — 0.964 Q08BV2 →
Q9H9V9 — 0.963 Q9H9V9 →
A2RUC4 — 0.963 A2RUC4 →
A2RSX7 — 0.962 A2RSX7 →
Q0IIB1 — 0.962 Q0IIB1 →
Q9DB26 — 0.961 Q9DB26 →
B2GUS6 — 0.960 B2GUS6 →
Q865R1 — 0.959 Q865R1 →
Q8BFT6 — 0.958 Q8BFT6 →
PAOX Peroxisomal N(1)-acetyl-spermine/spermidine oxidase 0.958 landscape →
B5XF11 — 0.957 B5XF11 →
Q5SRE7 — 0.957 Q5SRE7 →
Q9CXT6 — 0.956 Q9CXT6 →
P47823 — 0.956 P47823 →
Q9JLV6 — 0.955 Q9JLV6 →
Q5NVK5 — 0.955 Q5NVK5 →
A5GFZ6 — 0.955 A5GFZ6 →
O95396 — 0.955 O95396 →
Q8R123 — 0.955 Q8R123 →
HEXD Hexosaminidase D 0.954 landscape →
Q8BYR1 — 0.954 Q8BYR1 →
Q86U10 — 0.954 Q86U10 →
EIF2B5 Translation initiation factor eIF2B subunit epsilon 0.953 landscape →
Q5EA80 — 0.953 Q5EA80 →
Q921Q3 — 0.953 Q921Q3 →
A5A779 — 0.953 A5A779 →
Q561R2 — 0.953 Q561R2 →
Q3KQV9 — 0.953 Q3KQV9 →